Načítá se...
CLINICAL EFFICIENCY AND SAFETY OF FENOFIBRATE, A PPARα AGONIST, IN THE PATIENTS WITH DIABETESASSOCIATED OSTEOARTHRITIS: A CROSS-OVER PILOT STUDY
Sixteen female patients with diabetes-associated osteoarthritis (DAOA) participated in an openlabel, randomized, cross-over study. The mean patients’ age was 65.5 (±5.4) years, the patients were obese (mean body mass index, 35.8±5.7 kg/m2 ). They suffered from durable osteoarthritis (14.5±7.6 years)...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Russo |
| Vydáno: |
SPb RAACI
2017-05-01
|
| Edice: | Medicinskaâ Immunologiâ |
| Témata: | |
| On-line přístup: | https://www.mimmun.ru/mimmun/article/view/1219 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|